The NHS Innovation Service helps developers get their health technologies adopted by the NHS. The service provides coordinated and bespoke support from leading organisations, including NICE, with experience, knowledge, and expertise in supporting healthcare innovations.
Life sciences: how to get your product to market
A positive recommendation from NICE sends a powerful signal to the health and care system that your product should be adopted.
We work closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
Get a technology evaluated
We assess the clinical and cost effectiveness of new health technologies, translating complex evidence into useful and usable advice and guidance for the health and care system.
The first step in technology evaluation by NICE is product registration:
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline. It's used by horizon scanning organisations, including NICE, to help plan and prepare the NHS for the introduction of new medicines, and to support faster adoption.
How we can support you
Wherever you are in your planning process, our expertise can support you to:
collate strong evidence
provide advice on NICE evaluation programmes
understand and connect with the health and care system
demonstrate the value of your health technology
get new and innovative technologies adopted quickly.
From early innovation and evidence generation to market access. We work collaboratively with industry partners along the whole product pathway and post-launch.
Our NICE Advice service helps you optimise your approach at any point in product innovation and development, especially in the early stages. We can support you to: understand your product route to market, review your development and evidence generation plans, identify what matters most to patients, as well as the health and care system, and engage with the system during product development to support adoption and use.
Find out more about our evidence standards frameworks, and our AI and digital regulations service.
ILAP is a unique initiative which works with medicine developers early on to help get new medicines to patients faster. NICE is a key strategic partner in this work.
This pathway is designed to accelerate patient access to financially sustainable and effective healthtech.
Developers of new medicines can submit licensing applications through the MHRA) International Recognition Procedure IRP. It allows the MHRA to consider the expertise of trusted regulatory partners in other countries when authorising medicines. Companies considering this route should add relevant medicines to UK PharmaScan as early as possible to support the production of timely technology appraisal guidance.
EAMS allows important drugs to be used in clinical practice during the later stages of the regulatory process. We can help you navigate through the EAMS process. We do this by working with NHS England to offer engagement meetings.
NICE is such a big part of what the NHS listens to. It’s so important. It was fantastic to have NICE guidance for our product saying this is the right thing to do.
Lisa JonesProduct manager, cardiovascular diagnostics and services at Medtronic
How we've worked with life sciences companies
A digital health developer’s journey through NICE
From NICE digital health pilot to AI Award winner
Journey from NICE guidance to MedTech Funding Mandate
How we evaluate technologies
Find out how we choose which medicines and technologies we evaluate, the processes we follow and how we handle evidence.
Our health technology evaluation and topic selection manuals cover:
how we choose medicines and other health technologies to evaluate (topic selection)
the steps we follow in each evaluation (our processes)
how we collect and consider evidence (our methods).
Find published, in development and proposed evaluations: